BioXcel Therapeutics to Present at the Canaccord Genuity 2019 Annual Growth Conference
NEW HAVEN, Conn., July 31, 2019 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BTI”) (Nasdaq: BTAI) today announced that Dr. Vimal Mehta, Founder and Chief Executive Officer of BTI, will present [on its product candidates] at the Canaccord Genuity 2019 Annual Growth Conference being held August 6 – 8, 2019 in Boston. BTI is a clinical-stage biopharmaceutical development company that utilizes novel artificial intelligence approaches to identify and advance the next wave of medicines in neuroscience and immuno-oncology.
Details of the presentation below:
| Event: | Canaccord Genuity 2019 Annual Growth Conference |
| Date: | Wednesday, August 7, 2019 |
| Location: | InterContinental Boston Hotel, San Francisco Room |
| Time: | 1:00 – 1:25 PM ET |
In addition to his presentation, Dr. Mehta will be hosting 1-on-1 investor meetings at the conference. Investors attending the conference who are interested in meeting with BTI management should contact their Canaccord representative.
A live webcast of the presentation will be accessible through the Investors section of BTI's website at www.bioxceltherapeutics.com. Following the conference, a webcast replay will be archived on BTI’s website for 30 days.
About BioXcel Therapeutics, Inc.:
BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on drug development that utilizes novel artificial intelligence approaches to identify and advance the next wave of medicines in neuroscience and immuno-oncology. BTI’s drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. BTI’s two most advanced clinical development programs are BXCL501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neuropsychiatric disorders, and BXCL701, an orally administered systemic innate immunity activator designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer in combination with other immuno-oncology agents. For more information, please visit www.bioxceltherapeutics.com.
Contact Information:
BioXcel Therapeutics
The Ruth Group
Janhavi Mohite
646-536-7026
jmohite@theruthgroup.com
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
